Amgen announced Monday that the FDA has accepted its supplemental Biologics License Application for denosumab.
Amgen announced Monday that the FDA has accepted its supplemental Biologics License Application (sBLA) for denosumab (XGEVA). The application seeks to expand the monoclonal antibody’s currently approved indication for the prevention of fractures and other skeletal-related events in patients with bone metastases from solid tumors to include patients with multiple myeloma. The FDA set a Prescription Drug User Fee Act action date of February 3, 2018.
Amgen’s sBLA, submitted in April, is based on the data gathered in a phase 3, randomized, double-blind, multicenter study that met its primary endpoint of demonstrating non-inferiority of denosumab to zoledronic acid in delaying the time to first on-study skeletal-related event in patients with multiple myeloma. The study did not meet its secondary endpoints of demonstrating superiority of denosumab in time to first on-study skeletal-related event and delaying time to first-and-subsequent skeletal-related event.
“Multiple myeloma patients with fractures and other bone complications have a very poor prognosis,” says Sean E. Harper, MD, executive vice president of research and development at Amgen. “Bisphosphonates are the only approved class of agents for the prevention of skeletal-related events in this patient population,” he went on, citing kidney toxicity and acute phase reaction as potential adverse events related to treatment with bisphosphonates. “We look forward to potentially making XGEVA available as a novel option for patients with multiple myeloma,” Harper said.
Multiple myeloma is the second most common hematologic cancer, developing in plasma cells located in the bone marrow microenvironment. This cancer is typically characterized by osteolytic bone lesions and renal impairment. While over 90% of patients with multiple myeloma develop osteolytic lesions during the course of the disease, bisphosphonates are cleared by the kidneys and are associated with renal toxicity. Approximately 60% of patients with multiple myeloma have or will develop renal impairment over the course of the disease.
As denosumab is not cleared by the kidneys, it may provide an opportunity to prevent bone complications—responsible for significant morbidity in patients with multiple myeloma—without increased renal complications.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.